Latest Angina pectoris Stories
SAN DIEGO, April 15, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc.
LifeKeeper launches on the Indiegogo website the world’s first personal mobile system designed to real-time alert of circumstances which could be dangerous for health.
Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina.
MarketOptimizer.org adds Latest Report on “EpiCast Report: Acute Coronary Syndrome (ACS) – Epidemiology Forecast to 2022” to its store. Dallas, TX (PRWEB)
A study led by researchers at the University of California, San Diego School of Medicine shows that one of the most widely used systems for predicting risk of adverse heart events should be re-evaluated.
Patients with acute coronary syndrome who were treated with the experimental drug varespladib were more likely to experience additional cardiovascular events – including sudden death, heart attack and stroke – than those treated with placebo.
Stephen J. Nicholls, M.B.B.S., Ph.D., of the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, Australia, and colleagues determined the effects of varespladib, a drug that inhibits the enzyme secretory phospholipase A2 on cardiovascular risk in patients with acute coronary syndrome (ACS; such as heart attack or unstable angina).
New research shows that young or middle aged women with type 2 diabetes carry much greater risk for coronary artery disease than was previously understood.
Although coronary artery disease (CAD) causes as many deaths in women as it does men, preventative recommendations, such as lifestyle advice, aspirin and lipid-lowering therapy are still suggested less for women than men who are at the same risk.
- A woman chauffeur.
- A woman who operates an automobile.